In this randomized trial, among patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slowed the decline in the ...

Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory effects. In a phase 2 trial involving patients with idiopa ...

SAN FRANCISCO — Two doses of 52-week nerandomilast, a phosphodiesterase 4B inhibitor, reduced FVC decline vs. placebo in patients with idiopathic pulmonary fibrosis, according to results ...

SAN FRANCISCO — Two doses of 52-week nerandomilast, a phosphodiesterase 4B inhibitor, lowered FVC decline vs. placebo in patients with progressive pulmonary fibrosis, according to results ...

SAN FRANCISCO — The investigational oral agent nerandomilast was superior to placebo at slowing the decline in forced vital capacity (FVC) among patients with progressive pulmonary fibrosis (PF ...

Positive results of two phase 3 studies of nerandomilast were presented at the American Thoracic Society's Annual Congress (ATS, San Francisco, 16-21 May). The trials were conducted with ...

Nerandomilast, an investigational agent, met the primary endpoint of both phase III trials, FIBRONEER™-IPF and FIBRONEER™-ILD, significantly reducing the decline in forced vital capacity (FVC ...

Nerandomilast significantly reduced the decline in FVC compared with placebo, with adjusted differences of 67.2 mL for the 18 mg dose and 81.1 mL for the 9 mg dose (P < .001 for both).

In this randomized controlled trial, treatment with nerandomilast led to slower declines in forced vital capacity (FVC) in patients with progressive pulmonary fibrosis over 52 weeks 2. The occurrence ...

Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B (PDE4B). In preclinical models of lung fibrosis, nerandomilast showed antifibrotic and ...